AI Insight
Researchers are testing an experimental drug that fights mesothelioma by disabling PRX3, a protective antioxidant mechanism that cancer cells rely on to survive oxidative stress. In an early-phase clinical trial, the treatment controlled disease progression in 67% of patients with this aggressive asbestos-related cancer. The approach represents a novel strategy that exploits cancer cells' vulnerability to oxidative damage by removing their protective defenses.
Why it matters
This counterintuitive treatment approach offers hope for mesothelioma patients who currently have limited effective treatment options. If successful, the strategy of targeting antioxidant defenses could potentially be applied to other cancer types that rely on similar protective mechanisms.
Understand the Science
Scientists are testing a counterintuitive way to fight mesothelioma, an aggressive asbestos-linked cancer with few effective treatments. A new experimental mesothelioma drug kills cancer cells by disabling PRX3, an antioxidant defense that tumors use to survive intense oxidative stress. In an early clinical trial, it controlled disease progression in 67% of patients and produced encouraging survival results, raising hopes that the strategy could eventually be used against other cancers.
Source: New mesothelioma drug turns cancer’s own defenses against it